Neoadjuvant, biweekly, dose-dense chemotherapy with epirubicin and cyclophosphamide followed by docetaxel in primary breast cancer.

被引：0
|
作者：
Cramer, EM [1 ]
Moers, C [1 ]
Zarghooni, V [1 ]
Mallmann, P [1 ]
Warm, M [1 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：82S / 82S
页数：1
相关论文
共 50 条
  • [21] Dose-dense and sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab as neoadjuvant chemotherapy in stage II and III breast cancer.: A phase II and pharmacogenomic study.
    Sanchez-Rovira, P
    Duenas, B
    Cidraque, M
    Duenas, R
    Jaen, A
    Sanchez, A
    Martinez, E
    Medina, B
    Carrasco, E
    Lozano, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 29S - 29S
  • [22] A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
    Antolin, Silvia
    Mel, Ramon
    Ramos, Manuel
    Garcia-Palomo, Andres
    Almanza, Concepcion
    de Paz, Laura
    Calvo, Lourdes
    Alvarez, Elena
    Gonzalez, Ana
    Garcia-Mata, Jesus
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (09): : 686 - 691
  • [23] A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study
    Silvia Antolín
    Ramón Mel
    Manuel Ramos
    Andrés García-Palomo
    Concepción Almanza
    Laura de Paz
    Lourdes Calvo
    Elena Álvarez
    Ana González
    Jesús García-Mata
    Clinical and Translational Oncology, 2011, 13 : 686 - 691
  • [24] Neoadjuvant 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.
    Heller, W.
    Mazhar, D.
    Ward, R.
    Lowdell, C.
    Dudley, S.
    Sami, S.
    Carlo, P.
    Charles, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S157 - S157
  • [25] Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
    Khoshroo, Sara
    Sandoughdaran, Saleh
    Sabetrasekh, Parisa
    Hajian, Parastoo
    Bikdeli, Pegah
    Sabetrasekh, Parto
    Nasrollahi, Fatemeh
    Yeganeh, Ladan Mohammadi
    Naeini, Sepideh Jafari
    Mirzaei, Hamid Reza
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2021, 2021
  • [26] Dose-dense chemotherapy for primary breast cancer
    Kuemmel, Sherko
    Rezai, Mahdi
    Kimmig, Rainer
    Schmid, Peter
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2007, 19 (01) : 75 - 81
  • [27] Geparquinto: An interim safety analysis of epirubicin/cyclophosphamide followed by docetaxel with or without bevacizumab as neoadjuvant chemotherapy for primary breast cancer patients
    Von Minckwitz, G.
    Bauerfeind, I.
    Gerber, B.
    Eidtmann, H.
    Kaufmann, M.
    Costa, S. D.
    Loibl, S.
    Nekljudova, V.
    Untch, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with breast cancer with 4 or more positive lymph nodes
    Boy, D.
    Murialdo, R.
    Angelini, I.
    Panariello, M.
    Tixi, L.
    Sacca, V.
    Piccardo, A.
    Ballestrero, A.
    BREAST, 2009, 18 : S55 - S55
  • [29] Phase II study of neoadjuvant dose-dense docetaxel in stage II/III breast cancer.
    Chakravarthy, B.
    Mayer, I. A.
    Meszoely, I
    Means-Powell, J.
    Kelley, M. C.
    Grau, A.
    Johnson, D. H.
    McLaren, B. N.
    Broome, E. E.
    Pietenpol, J. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S148 - S148
  • [30] Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial
    Schneeweiss, A
    Schuetz, F
    Rudlowski, C
    Hahn, M
    Lauschner, I
    Sinn, HP
    von Fournier, D
    Sohn, C
    ANTI-CANCER DRUGS, 2005, 16 (09) : 1023 - 1028
12345